PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis c |
| Phenotype | C0002871|anemia |
| Sentences | 15 |
| PubMedID- 22097608 | Conclusion: main treatments of viral hepatitis combined with aplastic anemia were to treat primary hepatopathy and nucleoside analogue-based antiviral therapy, to provide symptomatic and supportive treatment for blood diseases. |
| PubMedID- 25834588 | Background: single-nucleotide polymorphisms (snp) in the inosine triphosphate pyrophosphatase (itpa) gene correlate with ribavirin (rbv)-induced anemia in patients with chronic hepatitis c (chc) receiving combination therapy. |
| PubMedID- 22181672 | Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis c following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype. |
| PubMedID- 21346688 | Role of nucleoside transporters slc28a2/3 and slc29a1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis c. |
| PubMedID- 21349541 | Conclusions: giant cell hepatitis combined with autoimmune hemolytic anemia requires rigorous treatment. |
| PubMedID- 23386076 | anemia management in patients with chronic viral hepatitis c. |
| PubMedID- 21643422 | In the cbv/lpv/r arm, two patients suffered from gastrointestinal discomfort, one developed anemia during co-administration of ribavirin for hepatitis c therapy and another one was admitted to hospital for an airway infection. |
| PubMedID- 22931407 | Hla-b*15:02 is associated with anemia in patients with chronic hepatitis c treated with pegylated interferon-alpha and ribavirin. |
| PubMedID- 23924660 | Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis c virus genotype 1 infection--a randomized trial. |
| PubMedID- 24413867 | Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis c virus infection in patients with sickle-cell anemia in saudi arabia. |
| PubMedID- 23945605 | It has long been recognized that clinical response is not solely dependent on pk, but there are many other factors relating to the status of the hiv-positive patient that also play a role.4,5 this has clearly been shown to be the case for maraviroc particularly when focusing on overall virologic success.2 for this reason, generalized additive models (gams) were employed to characterize the influence of prognostic factors (including exposure parameters) on sustained virologic response and incidence of anemia in patients with chronic hepatitis c6 and in hiv-1–infected patients in the etravirine phase iii clinical studies.7 gams allow potential predictors to enter linearly or nonlinearly, as appropriate for each case. |
| PubMedID- 21611106 | On the other hand, ebv-associated hepatitis could occur with aplastic anemia [1]. |
| PubMedID- 24879173 | Severe autoimmune hemolytic anemia in a patient with chronic hepatitis c during treatment with peg interferon alfa-2a and ribavirin. |
| PubMedID- 23226068 | A randomized trial comparing ribavirin dose reduction with administration of erythropoietin for the management of anemia in patients with chronic hepatitis c receiving boceprevir and peg-ifn-α-ribavirin has shown similar sustained virological response rates and safety profiles in both groups.51 therefore, reduction of the ribavirin dose in patients treated with peg-ifn-α-ribavirin and boceprevir appears to be an appropriate way to manage anemia. |
| PubMedID- 20698227 | Conclusion: this is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis c and we could not find any relation. |
Page: 1